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Introduction
Acute upper gastrointestinal bleeding represents a challenging problem with significant morbidity and mortality, despite advances in diagnosis and treatment [3] . Haemostasis attained at endoscopy reduces recurrent bleeding, the need for surgery and mortality in patients with bleeding peptic ulcers [4] [5] [6] .
Experimental data suggest that gastric acidity plays an important role in causing clot lysis in bleeding ulcers, thus impairing haemostasis [7] . Furthermore, a pH of <6 inhibits platelet aggregation [8] and of <5 inhibits plasma coagulation [9, 10] . It has been hypothesized that inhibiting acid production consolidates clot formation and reduces the risk of rebleeding [8] .
Irreversible inhibition of the H + /K + -ATPase proton pump, which varies between proton pump inhibitors (PPIs) [11] , allows more effective, direct suppression of acid secretion. While the role of adjuvant intravenous PPIs after endoscopic therapy has been confirmed in managing bleeding peptic ulcers [12] [13] [14] , the best route of administration remains uncertain [15] [16] [17] . A randomized controlled trial (RCT) comparing a frequent oral PPI with an intravenous (IV) PPI showed that the former achieved 24-h pH control similar to that of an IV bolus infusion, although the IV PPI reached a mean pH of 6 approximately 1 h sooner than oral PPI [18] .
Current guidelines recommend treatment with an IV bolus followed by continuous infusion of PPI in patients with high-risk stigmata after successful endoscopic therapy [19, 20] , while other guidelines state that a specific recommendation on the route of administration of PPIs cannot be made [21] . However, as shown by 24-h intragastric pH monitoring, oral PPIs may be able to replace IV PPIs in patients with bleeding peptic ulcers [18] . Two studies from Asia showed that oral PPIs as an adjunct to endoscopic treatment reduced the risk of recurrent bleeding by approximately 14-50% [22, 23] . Moreover, there was no difference between the same dose of various PPIs given either intravenously or orally with regard to increasing intragastric pH above 6 for 72 h after successful endoscopic haemostasis [24] .
Administration of IV PPI is more expensive and more complex to manage compared with the oral route. Several recent RCTs compared the efficacy of oral and IV PPIs in peptic ulcer bleeding but most of these were based on a small sample size [25] [26] [27] [28] [29] .
The only previous meta-analysis undertaken specifically to compare oral and IV PPIs showed equivalence but, again, was based on RCTS with small numbers [30] . A Cochrane meta-analysis, including five RCTs, comparing different PPI regimens failed to show superiority of any particular route of administration [15] . Since then, one further RCT has been published [31] , showing no statistical difference between oral and intravenous PPIs for all clinical outcomes assessed.
We present an up-to-date systematic review and metaanalysis comparing clinical outcomes with oral or IV PPIs in patients with bleeding peptic ulcers after endoscopic treatment, which included a trial [32] that was included in the meta-analysis undertaken by Neumann et al. [15] but excluded from the meta-analysis undertaken by Tsoi et al. [30] . A further study [24] included in the National Institute for Health and Care Excellence guidelines [21] comparing the effects of oral with IV PPIs on intragastric pH after endoscopic treatment was also included.
Methods
The recommendations of the Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) were used [33] . Methods of analysis and inclusion criteria were specified in advance and documented in a protocol according to Cochrane guidelines [34] . A PRISMA checklist is provided in the Supporting Information.
Eligibility
Types of study. RCTs comparing oral vs. IV PPIs. No language or publication status restrictions were imposed.
Types of participant. Patients admitted with symptoms of bleeding peptic ulcers undergoing endoscopic therapy to control bleeding were considered.
Types of intervention. Trials comparing clinical outcomes after oral or IV PPIs following endoscopic treatment.
Outcomes. The primary outcome measure was recurrent bleeding. Secondary outcomes included: need for surgery, 30-day mortality, need for a second endoscopic treatment, need for a blood transfusion and length of hospital stay.
Exclusions.
Patients with bleeding from upper gastrointestinal neoplasms or patients already on PPI treatment.
Identification and selection of studies
A medical literature search was performed by two authors (AT and MS) using MEDLINE, EMBASE, Cochrane Library and the ISI Web of Knowledge from January 1990 to February 2016. The full-text of each potentially eligible study was assessed by two authors (AT and RM) searching for references to relevant literature reviews to complement the computer searches. Keywords for the search were 'melaena', 'haematemesis', 'peptic ulcer haemorrhage', 'proton pump inhibitors', 'PPI', 'oral PPI', 'IV PPI', 'randomized controlled trials', 'meta-analysis', 'endoscopic treatment' and 'ulcer bleeding'. The search strategy is shown in Table 1 . Each article was read and analysed by two members of the research team (AT and RM).
Data extraction
All articles selected for relevance were evaluated independently two investigators (AT and MS). Extracted data were transcribed to specially prepared tables based on the Cochrane Review Group data extraction template. Two reviewers (AT and RM) included studies and extracted data, and disagreement was resolved by consensus.
The following data were extracted:
Descriptive data: First author, year and type of publication, country of origin, study setting, number of patients, age and gender of patients, type and dose of PPIs used, Forrest classification, ulcer site, ulcer size, presence of comorbidity, Rockall score and type of endoscopic treatment used.
Qualitative data: Random sequence generation, allocation concealment, blinding participant and personnel, blinding outcome assessment, incomplete outcome data, selective reporting and lost at follow-up.
Outcome data: Recurrent bleeding, and recurrent bleeding at 15 days and 30 days, need for a second endoscopic treatment, need for a blood transfusion, length of hospital stay, requirement for surgery and 30-day mortality.
Study quality
The characteristics of studies were assessed independently by two investigators (AT and RM) and are reported in Table 2 .
Potential sources of bias were evaluated by the Cochrane Risk tool [35] . The risk of bias tool evaluated the random sequence generation, allocation concealment, blinding of patients and investigators, blinding of outcome, incomplete outcome data, selective outcome reporting and other potential bias according to the Cochrane guidelines [35] .
Study outcomes
The primary outcome was recurrent bleeding, defined as the failure to control bleeding after the first endoscopic therapy. Secondary outcomes included the mean volume of blood transfused, duration of hospital stay in days, need for a second endoscopic treatment or surgery and mortality within 30 days following endoscopic therapy.
Statistical analysis
Meta-analysis. Data were synthesized using Review Manager software (version 5.1 for Windows, the Cochrane Collaboration, Oxford, UK). The odds ratio (OR) was used to analyse dichotomous data obtained from individual studies and the mean difference (MD) was used to calculate continuous variables. Recurrent bleeding, the need for surgery, the need for a second endoscopic treatment, and 30-day mortality are summarized as ORs with 95% confidence intervals. Hospital stay and volume of blood transfused were calculated as mean differences according to the Cochrane guidelines [36] . The random-effects model according to the method of Der Simonian and Laird [37] was used as a conservative approach, considering variations between studies.
Analysis of heterogeneity. In order to assess heterogeneity visually, the Forest plot was inspected. Finally, to confirm and quantify the presence of inconsistency, the I 2 statistic was used. Heterogeneity was significant at I 2 > 50% [38] . I 2 has been shown to be preferable to the test of heterogeneity when assessing inconsistency between studies [39] .
Publication bias. Publication bias was not assessed because of the low number of studies involved (<10 studies), according to the BMJ recommendation stating that the funnel plot and Egger test should only be included if the meta-analysis includes 10 or more studies as, when there are too few studies, the power of the tests is too low to distinguish chance from real asymmetry [40] . Despite a low power for detecting publication bias, with only nine eligible studies, a funnel plot (not shown) did hint at a possible lack of publication of small studies favouring IV over oral PPIs.
Sensitivity analysis. Sensitivity analysis was performed by removing each trial analysis in turn (to assess the influence of each individual study on the global analysis) and performing the meta-analysis using only studies of higher quality (the leave-one-out-method). Furthermore, we analysed trials using the fixed-effects model or randomeffects model and compared trials of lower quality vs. higher quality, in addition to identifying an outlier study using a sequential algorithm, as previously described and recommended [41] . We selected the first 72 h as the period for calculating the cumulative dose of PPI because this period includes the majority of rebleeding episodes [42] . Furthermore, studies were categorized according to the cumulative dose of PPI received within the first 72 h of treatment, as follows: low-dose studies: ≤120 mg 72 h -1 or high-dose studies:
≥600 mg 72 h -1 . We selected a cut-off above 240 mg 72 h
as high-dose oral PPI. The risk of bias in individual studies, across studies and within studies according to the Cochrane recommendation [35] are provided. The meta-regression was not performed because fewer than 10 trials were included in the meta-analysis [36, 43] .
Results
Study selection. The initial search identified 3325 abstracts after duplicates were removed. Of these, 3225 studies were excluded after evaluating title and abstract, 100 full-text articles were assessed for eligibility and 91 were excluded as shown in the PRISMA flow chart (Figure 1 ). Finally, nine RCTs comprising eight full-text articles [24-29, 31, 44] and one in abstract form [32] , published between 2004 and 2014, were included in the meta-analysis. These included patients from the United States, Turkey, Iran, Taiwan, Hong Kong, Italy and Korea.
Characteristics of included trials
In the nine RCTs [24-29, 31, 32, 44] , 1036 subjects were allocated to receive oral PPIs (n = 518) or IV PPIs (n = 518). Four trials [25, 26, 29, 32] were also classified as having a high risk of performance and detection bias according to the Cochrane definition [35, 36] . The number of patients in the individual trials ranged from 25 to 211, with a mean age of 60 years, with 71.1% male ( Table 2) . We did not evaluate or report Table 2) . Different PPIs were used in these studies, including pantoprazole [25, 27, 29, 48] , omeprazole [26, 27, 44] , rabeprazole [26] , lansoprazole [28] and esomeprazole [28, 31, 32] (Table 2) . In all trials, endoscopic procedures were performed within 24 h of admission. Endoscopic treatment was not carried out in one trial [44] ; in one trial, only adrenaline was used [26] ; in another trial, adrenaline was used as the only approach in 66% of cases [27] (Table 3 ).
Study quality
The risk of bias, according to the Cochrane risk of bias tool, was not significant (Figure 2A ,B).
Primary outcome
All trials reported recurrent bleeding (Table 1) . Heterogeneity between trials was not statistically significant (I 2 = 0%; P = 0.67) and the pooled results showed no significant differences concerning recurrent bleeding between oral and IV PPIs (OR 0.93, 95% CI 0.61, 1.46; P = 0.77) ( Figure 3 and Table 4 ).
Secondary outcomes
Secondary outcomes are reported in Table 4 , showing the need for a second endoscopic treatment (OR 0.69, 95% CI 0.39, 1.21; P = 0.19), a need for surgical intervention (OR 0.77, 95% CI 0.25, 2.40; P = 0.65) and 30-day mortality (OR 0.89, 95% CI 0.27, 2.93; P = 0.84) ( Figure 4 and Table 4 ). The mean number of transfusions (MD À0.03 units, 95% CI -0.26, 0.19 units; P = 0.76) was equivalent in both groups ( Figure 5 ). There was no statistically significant difference among patients receiving oral or IV PPIs in terms of length of hospital stay (MD À0.61 days, 95% CI -1.45, 0.23 days; P = 0.16) ( Figure 5 ).
Exploring source of heterogeneity
Heterogeneity was found in the length of hospitalization (I 2 = 78%; t 2 = 0.74, df = 5; P = 0.003) but a sensitivity analysis looking at higher-quality trials did not show a difference. We used both fixed-and random-effects models for all outcomes, and these did not differ. On the contrary, for length of hospital stay we used the most appropriate random-effects model, which considers variance between studies, because of the presence of heterogeneity (I 2 = 78%), and this showed that the groups had an equal length of hospital stay (MD -0.61, 95% CI -1.45, -0.23; P = 0.16). We also took into consideration the clinical source of heterogeneity and statistical heterogeneity, as described previously [49] .
Figure 1
Prisma flow chartGORD, gastro-oesophageal reflux disease; PPI, proton pump inhibitor Table 3 Baseline characteristics of included trials To assess the reason for statistical heterogeneity, we performed a sequential algorithm, as described by Patsopoulos et al. [41] allowing the identification of an outlier study [28] . The omission of this study reduced the estimated heterogeneity to 0%. This study had an unclear risk of bias in blinding because it did not address the outcome that could have justified the heterogeneity found. Finally, we analysed and compared primary and secondary outcomes (except for those data that were not available in the trials), subdividing trials into high quality (low/unclear risk of bias) and low quality (high risk of bias), as shown in Table 5 .
Subgroup analyses
In the subgroup of trials comparing high-dose (i.e. ≥600 mg 72 h Intravenous vs. oral PPIs for bleeding peptic ulcers outcomes analysed, except for the need for blood transfusion, which favoured oral PPIs (MD -0.76 units, 95% CI -1.27, 0.26; P = 0.003) ( Figure 6 ). Length of hospital stay was significantly shorter with oral treatment (MD À1.34 days, 95% CI -1.88, 1.79; P = 0.00001; I 2 = 84%) but when the outlying trial [28] was excluded, no statistically significant difference was observed (MD À0.12 days, 95% CI -1.0, 0.76; P = 0.79; I 2 = 0%).
Four trials [23, 25, 26, 28] reported outcomes in 538 patients with high-risk stigmata (i.e. spurting, oozing or nonbleeding vessel); recurrent bleeding was similar between the oral and IV PPI groups (OR 0.93, 95% CI 0.51, 1.70). Three Figure 4 Forest plot of comparison between oral and IV PPIs for (A) need for surgery, (B) mortality and (C) EHT, need for a second endoscopic treatment. CI, confidence interval; IV, intravenous; M-H, Mantel-Haenszel; PPI, proton pump inhibitor trials [26, 28, 31] reported recurrent bleeding after 15 days in 500 patients, with no statistically significance difference observed between the two groups (OR 1.11, 95% CI 0.61, 2.03; P = 0.72) and no heterogeneity (I 2 = 0%).
Five trials [25, 27, 29, 31, 44] 
Discussion
The present meta-analysis included nine RCTs comparing treatment efficacy between oral and IV PPIs in patients with bleeding peptic ulcers following endoscopic treatment. Oral PPIs were found to be equivalent to IV PPIs in regard to the risk of recurrent bleeding, need for blood transfusion, need for repeated endoscopy, length of hospital stay, need for surgery and overall mortality.
A RCT demonstrated that high-dose IV PPI (80 mg bolus followed by a continuous infusion of 8 mg h À1 for 72 h) was more effective than a standard IV dose of PPI (40 mg bolus twice a day for 72 h) in reducing rebleeding, blood transfusion requirement and length of hospital stay [50] . By contrast, subgroup analysis showed that high-dose IV PPIs were equivalent to low-dose IV PPIs for all outcomes considered. A subgroup analysis comparing a high-dose oral PPI to a high-dose IV PPI demonstrated no statistically significance difference for any of the outcomes considered, except for the need for a blood transfusion, which favoured the highdose oral PPI. In the present meta-analysis, oral PPIs showed similar efficacy compared with IV PPIs. One possible explanation might be that both oral and IV PPIs display equal efficacy in maintaining intragastric pH >6 over 24 h [18] .
Previous studies showed that the inhibition of gastric acid secretion with 40 mg oral pantoprazole compared with a similar IV dose yielded a similar result, with comparable rebleeding rates in bleeding peptic ulcers [51, 52] . Two previous studies from Asia showed that oral PPIs after endoscopic treatment reduced the risk of recurrent bleeding to between 17% and 50% [22, 23] , although these results may not be applicable generally to Caucasian populations because of underlying differences in pharmacodynamic profilesfactors that may favour the acid-suppressive effect of a given dose of a proton-pump inhibitor in Asian patients [17] .
Some endoscopic stigmata (e.g. spurting, oozing and nonbleeding vessel) are at high risk of recurrent bleeding [53, 54] . The present meta-analysis included some low-risk patients with Forrest classification IIc or III. These patients may have a lower risk of recurrent bleeding, which could explain the comparable efficacy of oral and IV PPIs. Our analysis showed that oral and IV PPIs are associated with an equal need for blood transfusions, in agreement with the results of the meta-analysis by Tsoi et al. [30] ; however, that meta-analysis showed that oral PPIs are associated with a reduced hospital stay compared with IV PPIs [30] . There may have been methodological and clinical reasons for the difference between this finding and that of the present report.
The RCTs included in the meta-analysis by Tsoi et al. [30] that assessed such outcomes were heterogeneous (I 2 = 82%), and the authors used a fixed-effects model instead of a random-effects one, despite the apparent heterogeneity between studies (I 2 = 82%), and this could have influenced the result. Our meta-analysis evaluated the same outcome by including the same RCTs, with the exception of our addition of the more recent trial by Sung et al. [31] , but used the random method described by Der Simonian and Laird [37] as a conservative approach and based on the heterogeneity of the studies. Another important clinical consideration is that, theoretically, even though the use of oral PPIs would allow an early discharge, in reality, patients with a high risk of rebleeding would not be discharged early, to avoid medico-legal problems.
Therefore, oral PPIs are ideally indicated for patients discharged from accident and emergency departments with a low risk of endoscopic stigmata, and also as a replacement for IV PPIs in hospitalized patients, as a cost-saving exercise.
Theoretically, the analysis of each subgroup of bleeding stigmata could help to improve our understanding of the differences in treatment efficacy between oral and IV PPIs, but the relevant data were not extractable from the original publications due to the limited sample size.
In the present meta-analysis, we could only select for analysis subgroup trials on high-risk stigmata patients, in whom recurrent bleeding in those using oral and IV PPIs was similar.
A Cochrane review by Neumann et al. [15] included five RCTs, four of which were classified as having a high risk of bias and the other [44] as having an unclear risk of bias. The 72-h cumulative dose of PPI was higher in the IV than in the oral regimen, and three of the studies used high-dose PPI (≥600 mg 72 h -1 ) and two used low-dose PPI (200 mg 72 h -1 ). Neumann et al. concluded that there was no difference between oral and IV PPIs in the outcomes analysed. Furthermore, they performed a meta-regression showing that the route of PPI administration was not significantly associated with treatment effects [15] . However, it should be pointed out that the use of meta-regression should generally not be considered when there are fewer than 10 studies in a meta-analysis [36, 43] . There were some clinical and methodological limitations in the meta-analysis by Tsoi et al. [30] , as summarized in Table 7 . First, the study was likely to have been underpowered owing to the low number of patients included (only 615) for a rare rebleeding rate as the primary outcome because of the underpowered RCT included as pointed out by the same authors.
Secondly, the lack of blinding in most of the trials included in the meta-analysis by Tsoi et al. [30] was also a key limitation due to the fact that all of the included trials reported a short follow-up period, which might have resulted in an observer bias among physicians and patients. As a result, the overall quality scores of included trials were weak. Thirdly, individual trials included patients reported in trials someone have a high risk stigmata of rebleeding compared to others, and the results may not be applicable to patients who are at high risk of rebleeding. In addition, the statistical data obtained from the available literature cannot be used in a meta-analysis of individual patients by different stigmata. Moreover, endoscopic therapies were applied heterogeneously among the trials; patients were selectively treated by epinephrine injection alone, thermocoagulation or haemoclips. A meta-analysis proved that the application of haemoclips is superior to injection alone but comparable to thermocoagulation for definitive haemostasis [6] so the use of epinephrine injection alone should be avoided.
In addition, available and selected trials in the metaanalysis by Tsoi et al. used different pharmacokinetic characteristics, including pantoprazole, omeprazole, rabeprazole, lansoprazole and esomeprazole. The pharmaceutical formulas of these PPIs are similar but not identical, so they can potentially have different efficacies. Subgroup analysis based on different PPIs can be assessed but the available sample size is too small. Finally, IV PPIs require continuous infusion in hospital for at least 3 days and therefore cannot be compared with oral PPIs in terms of the duration of hospitalization. IV PPIs have been shown to reduce recurrent bleeding after endoscopic treatment of bleeding peptic ulcers [12, 14] . The Table 7 Limitations of the meta-analysis by Tsoi et al. [30] according to the PRISMA statement for reporting systematic review and meta-analysis by Liberati et al. [33] Blood transfusion requirement with high-dose oral vs. high-dose intravenous PPI. CI, confidence interval; IV, intravenous; PPI, proton pump inhibitor; SD, standard deviation study by Tsoi et al. [30] showed that the efficacy of oral PPIs is similar to that of IV PPIs, but the conclusions that can be drawn from this study are limited by an insufficient sample size [30] . In view of the scarcity of economic resources, the cost of medical treatment is of considerable importance for hospital budgets. The cost of administering PPIs is determined by the nature of the pharmacotherapy; therefore, IV PPIs are far more expensive than orally administered forms [55] because they require dedicated IV lines, nursing care and continuous clinical monitoring, contributing to a longer hospitalization and higher costs. Conversely, the use of oral PPIs allows cost savings for healthcare systems as such patients can be discharged earlier.
A cost-effectiveness analysis performed by Spiegel et al. [56] , using a decision analysis to measure the clinical and economic outcomes of three different modes of PPI administration, showed that oral PPIs had a cost-effectiveness advantage over the IV route. However, these findings were not consistent with previous studies, which showed that IV PPIs were likely to be both more efficacious and cost effective when compared with oral PPIs [57, 58] .
Our systematic review, although adding a new trial [31] and a trial not previously reported [24] in other systematic reviews [15, 30] , had some limitations. Fifty per cent of the trials included in our meta-analysis were at a high risk of performance and detection bias. Furthermore, the sample size in some of the RCTs included was too small, resulting in studies that were underpowered to demonstrate a statistically significant difference between the two groups (oral vs. IV), leading to unreliable conclusions which would have limited the strength of our meta-analysis. To solve the problem of underpowering of the meta-analysis, a non-inferiority trial could be carried out, in which the maximum mean differences would be prespecified; however, the cost of such a trial could not be justified.
Finally, it should be pointed out that a systematic review of RCTs represents the highest level in the hierarchy of studies [59, 60] . Until future studies produce different data, the present study provides the best evidence to date.
In conclusion, the present meta-analysis showed that oral and IV PPIs have a similar efficacy after endoscopic treatment in controlling recurrent bleeding, the requirement for surgery and mortality in patients with peptic ulcer bleeding from different stigmata. Oral PPIs probably present a cost-saving approach in hospital administration. A subgroup analysis showed that the need for blood transfusion was significantly lower in the oral group when comparing high-dose oral PPIs to high-dose IV PPIs.
Large, well-designed RCTs are needed to allow a definitive conclusion to be drawn.
